{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016160","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.510487+00:00","generated_at":"2026-06-15T06:22:37.617188+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Matinas BioPharma concludes BioNTech mRNA collaboration, plans Phase 3 trial for MAT2203 antifungal","bullets":["BioNTech oral mRNA collaboration ended; in vivo oral study showed no activity, but systemic delivery and stability demonstrated.","Company plans to submit revised Phase 3 trial design for MAT2203 in aspergillosis and other IFIs in Q2 2023.","Seven patients with IFIs treated under compassionate use; oral MAT2203 showed safety and efficacy in diverse infections.","Cash position sufficient to fund operations into second half of 2024.","Expanded collaboration with National Resilience for mRNA/oligonucleotide delivery; initial data expected Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016160","json":"https://secwatch.observer/filing/0001493152-23-016160.json","markdown":"https://secwatch.observer/filing/0001493152-23-016160.md","text":"https://secwatch.observer/filing/0001493152-23-016160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223016160/0001493152-23-016160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223016160/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:22:37.617188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eb5639531c3ce6657c8c2f4ad0d934d15f58371d","claim":"Matinas BioPharma Holdings, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 10, 2023, Matinas BioPharma Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223016160/0001493152-23-016160-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}